{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-054309","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.536855+00:00","generated_at":"2026-05-23T14:12:34.543240+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Alaunos directors convert $139K deferred fees to equity: shares + options","bullets":["Total deferred board service fees of $139,000 from Q3 2024 through Q1 2025 converted to equity.","Issued 38,269 common shares with aggregate fair value of $111,750.","Granted 10,904 fully vested stock options at $2.92 exercise price, aggregate fair value $27,250.","Board elected equity over cash under Non-Employee Directors Compensation Policy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-054309","json":"https://secwatch.observer/filing/0000950170-25-054309.json","markdown":"https://secwatch.observer/filing/0000950170-25-054309.md","text":"https://secwatch.observer/filing/0000950170-25-054309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025054309/0000950170-25-054309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017025054309/tcrt-20250415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:12:34.543240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}